Tag: Cervical Cancer
-
Excluding Cervical Serous Carcinoma from WHO Classification
Introduction In the latest revision by the World Health Organization (WHO), cervical serous carcinoma has been excluded from the classification of primary cervical tumors. This decision reflects significant advances in our understanding of cervical cancers’ pathology and epidemiology. Understanding Cervical Serous Carcinoma Cervical serous carcinoma, particularly high-grade serous carcinoma, is a rare entity in the…
-
Research Advocates WHO Revision: Exclude Cervical Serous Carcinoma
Introduction to Cervical Serous Carcinoma Cervical serous carcinoma, previously considered a significant entity in gynecological oncology, has been highlighted in recent discussions regarding its classification. The World Health Organization (WHO) had categorized high-grade serous carcinoma as a notable diagnosis within cervical biopsies. However, in their 2020 revisions, the WHO has moved to exclude this type…
-
A Major Leap in Cervical Cancer Prevention in Peru
In a groundbreaking development for public health, Peru has officially integrated the nine-valent vaccine against the Human Papillomavirus (HPV) into its National Vaccination Schedule. This significant measure aims to combat cervical cancer, a disease that has posed serious health risks for women across the nation. Cervical cancer, which can often arise from persistent HPV infections,…
-
A New Hope: The HPV Vaccine in Peru’s Fight Against Cervical Cancer
In a remarkable advancement in public health, the Ministry of Health in Peru has officially included the nonavalent vaccine against the Human Papillomavirus (HPV) into the National Vaccination Schedule. This pivotal decision aims to curb the incidence of cervical cancer, a disease that affects thousands of women across the nation. The introduction of the HPV…
-
Peru’s Landmark Step in Cervical Cancer Prevention
In a significant advancement in public health, Peru has taken a decisive step in the fight against cervical cancer. The Ministry of Health (Minsa) announced the incorporation of the nonavalent vaccine against the Human Papillomavirus (HPV) into the National Vaccination Schedule. This new vaccine is projected to protect against 90% of cervical cancer cases, a…